Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088394 | 0.83 | MAPT (0.43) | HPGDMEN1KMT2A | |
| SCHEMBL3020612 | 0.74 | HPGD (0.43) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL946099 | 0.71 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL67697 | 0.70 | MEN1 (0.42) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4093765 | 0.69 | CNR2 (0.40) | NTRK1ABL1JAK2JAK3CNR2 | |
| SCHEMBL902454 | 0.68 | ASIC3 (0.42) | MEN1KMT2A | |
| SCHEMBL15057213 | 0.68 | SLC6A4 (0.42) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17601006 | 0.67 | MEN1 (0.36) | SHMT1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16673629 | 0.65 | MEN1 (0.33) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL22366419 | 0.64 | CYP1A2 (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | NTRK1 3954/4885ABL1 3168/4885HPGD 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.